NanoViricides, Inc. (NYSE:NNVC) Sees Large Increase in Short Interest

NanoViricides, Inc. (NYSE:NNVC) was the recipient of a significant growth in short interest in May. As of May 31st, there was short interest totalling 134,900 shares, a growth of 92.4% from the May 15th total of 70,100 shares. Based on an average trading volume of 151,700 shares, the days-to-cover ratio is currently 0.9 days. Approximately 0.9% of the company’s stock are short sold.

NanoViricides Stock Down 3.0%

Shares of NYSE:NNVC traded down $0.05 on Monday, hitting $1.47. 200,079 shares of the company traded hands, compared to its average volume of 238,850. NanoViricides has a 52 week low of $0.94 and a 52 week high of $2.55. The stock has a 50 day simple moving average of $1.39 and a 200-day simple moving average of $1.34. The company has a market cap of $23.55 million, a PE ratio of -2.03 and a beta of 0.91.

Hedge Funds Weigh In On NanoViricides

Several institutional investors and hedge funds have recently modified their holdings of NNVC. Wealth Enhancement Advisory Services LLC bought a new position in shares of NanoViricides during the first quarter valued at $26,000. XTX Topco Ltd purchased a new stake in shares of NanoViricides during the first quarter valued at $60,000. Virtu Financial LLC purchased a new stake in shares of NanoViricides during the fourth quarter valued at $91,000. Geode Capital Management LLC boosted its position in shares of NanoViricides by 28.7% during the fourth quarter. Geode Capital Management LLC now owns 143,313 shares of the company’s stock valued at $205,000 after buying an additional 31,956 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its position in shares of NanoViricides by 26.8% during the fourth quarter. Renaissance Technologies LLC now owns 145,700 shares of the company’s stock valued at $208,000 after buying an additional 30,800 shares during the last quarter. 10.30% of the stock is currently owned by institutional investors.

About NanoViricides

NanoViricides, Inc, a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases.